July 5, 2023
VANCOUVER — At THE Myopia Meeting held here June 11, 2023, Kim Kochendorfer, Myopia Management Specialist, Optician, presented on behalf of HOYA Vision Care, discussing the company’s D.I.M.S. (defocus incorporated multiple segments) technology, MiYOSMART lenses for myopia control, and the latest release – MiYOSMART sun range.
Six-Year Study Data
Kochendorfer opened the presentation with a breakdown of HOYA’s six-year clinical trial data, which was recently published in Scientific Reports:
“We had a group of children that were in D.I.M.S. technology for the entire six years. We had a group that started in D.I.M.S. and then switched back to regular single vision. Then we had a group that started in single vision, went to D.I.M.S., and stayed in D.I.M.S., and a group that started in regular single vision switched to D.I.M.S. and went back to single vision later. So, this gives us a lot of interesting information about what happens over time as a child wears D.I.M.S. technology, but also what happens when they stopped.”
Kochendorfer highlighted graphs from the six-year data that compared each of the different groups involved in the study and their outcomes over time. The first chart compared group one, which was the children who stayed in the D.I.M.S. technology for the entire six years, against the children that stopped at the 42-month mark.
“Group one had less than one-diopter average cumulative progression over six years – 0.92 of a diopter of progression on average over six years,” Kochendorfer said. “These are absolutely incredible results. We also had 0.6 mm average cumulative progression of axial length growth. So, that represents on average 0.1 mm per year. The ultimate goal of myopia management is to restore emmetropic eye growth, which is about 0.1mm per year, so we have achieved the goal. Now if we look at the children who switched out of the D.I.M.S. technology at the 42-month mark, their progression was comparable to scorm data of age normative children’s progression in regular single vision lenses, so we can conclude that there was no rebound effect.
“For the children that started in single vision and then moved to D.I.M.S. and stayed in D.I.M.S. technology, there was a contrast of fast progression at the beginning of the study, and then their progression significantly slowed. On the other hand, for the children that started with single vision, went to D.I.M.S. technology, and then went back to regular single vision, there was also a great deal of contrast. During the time that they were in D.I.M.S. there was minimal to no progression, whereas progression was significant while they were in the regular single vision lens.
Conclusions from the Six-Year Data
“This is the longest running myopia control spectacle lens study today, which we’re very proud of. You have a legacy of accurate scientific results showing these lenses are effective. We had treatment effects sustained over six years with an average cumulative progression of less than one diopter, an average axial elongation of point one millimeter per year, and no rebound effect. These are clinical results that you can trust and you can believe in. HOYA has taken a strong stance to report our clinical data conservatively and scientifically, and we are committed to continuing to stay up to date in how these children’s journeys go in MiYOSMART.
Myopia Education at the Forefront
“Part of our commitment to myopia management as the standard of care is not only to report on HOYA’s MiYOSMART D.I.M.S. technology data, but we also want to keep you well informed and educated. We’ve created a learning platform, Myopia.HOYAVisionLearningCenter.com. This is a collection of data about myopia management in general that’s interactive – there are videos, there are papers you can download, all collected in one spot for an easy-to-access platform where you can get even more information on myopia management.
“Another part of this commitment is that we collect global expert consensus on hot topics like combination treatment of spectacle lenses with atropine, or our latest, which is daylight and myopia management. In this expert consensus, one of the key takeaways is that more than 80 minutes per day of outdoor time prevents the onset of myopia. Most eye care professionals are now recommending at least two hours a day of cumulative outdoor time as a first line of defense for myopia management, and it is a common theme in our myopia management treatments that we prescribe.
Treating Myopia Outdoors
“We also found that the longer a treatment is worn, whatever that treatment may be, the greater the effectiveness. We want to make sure these children are spending time outside and continuing to wear their myopia treatment. We also know that intense light causes long term eye damage, glare, and reduces visual performance. We want to make sure that children are protected while they are outside but also enjoying their time and experiencing the beauty of outdoors, with added comfort, and the experts also noted that photophobia is common in atropine patients. From this expert consensus, we can clearly see that an option that offers myopia management, as well as protection and comfort from intense sunlight, is definitely a need in this space.
“ In response to this need, we have launched MiYOSMART Sun options. First, available now is MiYOSMART Chameleon. This is our photochromic option. It’s a photochromic designed with children in mind. It activates very quickly, and it fades back really quickly, too. Children can have two-in-one myopia management with protection from the sun. They get uninterrupted comfort outdoors, and they don’t have to worry about a long fade-back time. The lens is really clear in it’s inactivated state, and they look fantastic.
“In July, we’re going to be launching our polarized option, which will be a great choice for kids who are experiencing a little bit more light sensitivity or if they are in combination treatment, you can offer a polarized option in addition to a clear, or photochromic pair for superior sun protection and uninterrupted myopia management.”